The Dubousset Functional Test: a reliable and valid test in early stage Parkinson’s disease patients


Abit Kocaman A., Aydoğan Arslan S., Bozkurt Y. E., Coşkun E.

Neurological Sciences, cilt.45, sa.7, ss.3137-3146, 2024 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 45 Sayı: 7
  • Basım Tarihi: 2024
  • Doi Numarası: 10.1007/s10072-024-07359-1
  • Dergi Adı: Neurological Sciences
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CINAHL, Index Islamicus, MEDLINE, Psycinfo
  • Sayfa Sayıları: ss.3137-3146
  • Anahtar Kelimeler: Dubousset Functional Test, Outcome measures, Parkinson’s disease, Physical function, Reliability, Validity
  • Ankara Yıldırım Beyazıt Üniversitesi Adresli: Hayır

Özet

Introduction: Dubousset Functional Test (DFT) is an assessment test evaluating the functional capacity and dynamic balance. The study aimed to examine the reliability, validity, and responsiveness of the DFT in early stage Parkinson’s disease (PD) patients. Methods: This was a cross-sectional study. Thirty-three early stage PD patients were recruited. The DFT was performed along with the Timed Up and Go (TUG) test, dual-task TUG, Functional Reach Test (FRT), 3-m backward walk test (3MBWT), Tinetti Performance-Oriented Mobility Assessment (POMA), and Berg Balance Scale (BBS). Results: The test–retest reliability of the subcomponents of the DFT was excellent. The ICCs were as follows: 0.952, 0.955, 0.917, and 0.919, respectively. The correlation with subcomponents of DFT and TUG, dual-task TUG, FRT, 3MBWT, BBS, and POMA was found to be statistically significant (p < 0.05). The standard measurement errors of the subcomponents of the DFT were 1.45, 1.39, 1.70, and 1.57, respectively. The minimal clinically important difference (MCID) of the subcomponents was 2.05, 1.97, 2.41, and 2.22, respectively. Conclusion: The DFT is a reliable, valid, and easy-to-administer tool in assessing the balance and physical function of early stage PD patients.